QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
NASDAQ:IDXG

Interpace Biosciences - IDXG Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$2.39
$2.60
50-Day Range
$4.75
$10.40
52-Week Range
$2.57
$10.42
Volume
1,802 shs
Average Volume
3,285 shs
Market Capitalization
$10.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IDXG stock logo

About Interpace Biosciences (NASDAQ:IDXG) Stock

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Receive IDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Interpace Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IDXG Stock News Headlines

PDI Living Off Its Past Success
Interpace Diagnostics Group, Inc. (IDXG)
PDI: Stomaching Short Term Pain For Long Term Gain
Interpace Biosciences begins $30M rights offering
PDI: A Fresh Look Following The Merger
Interpace Biosciences Inc. (IDXG)
See More Headlines

Receive IDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Interpace Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IDXG Company Calendar

Last Earnings
11/10/2021
Today
8/15/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Services
Sector
Medical
Current Symbol
NASDAQ:IDXG
CUSIP
69329V10
Employees
152
Year Founded
N/A

Profitability

Net Income
$-14,940,000.00
Pretax Margin
-32.13%

Debt

Sales & Book Value

Annual Sales
$41.31 million
Book Value
($10.16) per share

Miscellaneous

Free Float
1,971,000
Market Cap
$10.55 million
Optionable
Not Optionable
Beta
1.01

Key Executives

  • Dr. Thomas W. Burnell Ph.D. (Age 58)
    Pres, CEO & Director
    Comp: $425k
  • Mr. Thomas John Freeburg Ph.D. (Age 52)
    Chief Accounting Officer, CFO, Treasurer & Sec.
  • Dr. Sydney D. Finkelstein
    Chief Scientific Officer
  • Dr. Alidad Mireskandari M.B.A.
    Ph.D., Chief Devel. Officer
  • Mr. Patrick Kane
    VP & Corp. Controller













IDXG Stock - Frequently Asked Questions

Should I buy or sell Interpace Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Interpace Biosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" IDXG shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IDXG, but not buy additional shares or sell existing shares.
View IDXG analyst ratings
or view top-rated stocks.

When is Interpace Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our IDXG earnings forecast
.

How were Interpace Biosciences' earnings last quarter?

Interpace Biosciences, Inc. (NASDAQ:IDXG) issued its earnings results on Wednesday, November, 10th. The business services provider reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.62) by $0.22. The business services provider earned $9.47 million during the quarter, compared to analyst estimates of $11.50 million.

What other stocks do shareholders of Interpace Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Interpace Biosciences investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Histogenics (HSGX), Johnson & Johnson (JNJ), SCYNEXIS (SCYX), Cisco Systems (CSCO), Trevena (TRVN) and TherapeuticsMD (TXMD).

What is Interpace Biosciences' stock symbol?

Interpace Biosciences trades on the NASDAQ under the ticker symbol "IDXG."

What is Interpace Biosciences' stock price today?

One share of IDXG stock can currently be purchased for approximately $2.44.

How much money does Interpace Biosciences make?

Interpace Biosciences (NASDAQ:IDXG) has a market capitalization of $10.32 million and generates $41.31 million in revenue each year.

How many employees does Interpace Biosciences have?

The company employs 152 workers across the globe.

How can I contact Interpace Biosciences?

Interpace Biosciences' mailing address is MORRIS CORPORATE CENTER 1 BUILDING C 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054. The official website for the company is www.interpace.com. The business services provider can be reached via phone at 855-776-6419, via email at jgreen@edisongroup.com, or via fax at 862-207-7820.

This page (NASDAQ:IDXG) was last updated on 8/15/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.